BioPharm Systems announced that it is unveiling a new service to help life sciences companies maximize the return on investment for Oracle's Siebel Clinical Trial Management System (CTMS). The new BioPharm Systems Siebel Clinical Process Reengineering service extends the company's existing clinical trial management practice offerings.
BioPharm Systems' Siebel Clinical Process Reengineering service aims to allow sponsors and clinical research organizations to reduce cost, boost productivity, and increase compliance. After an analysis of a company's organizational structure, user roles and task divisions, training materials, standard operating procedures, and other process documentation that involve Siebel Clinical, BioPharm Systems will make sound recommendations for improving efficiencies around the use of their CTMS.
Members of BioPharm Systems' clinical trial management practice have been implementing Siebel Clinical since its inception and have experience in the system itself and in the best practices surrounding its use. The company's pre-configured and enhanced version of Siebel Clinical, ASCEND, was recently presented with the 2011 Innovation Award for Excellence in Technology in Health Sciences from the Oracle Health Sciences User Group. BioPharm Systems also recently received an Oracle PartnerNetwork North America Titan Awards Honorable Mention in the Oracle Accelerate for Midsize Companies category.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.